[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.1.15. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 10, 1991

Estrogen Replacement Therapy and Risk of Breast Cancer-Reply

Author Affiliations

Brigham and Women's Hospital Channing Laboratory Boston, Mass
Harvard Medical School Boston, Mass

Brigham and Women's Hospital Channing Laboratory Boston, Mass
Harvard Medical School Boston, Mass

JAMA. 1991;265(14):1825. doi:10.1001/jama.1991.03460140052015

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

In Reply. —  Dupont suggests that the increased risk of breast cancer among current users of estrogen replacement therapy may be due, in part, to greater surveillance and early detection, basing this hypothesis on our crude rates of breast cancer. As shown in Table 2 of our article, age is strongly related to use of estrogen therapy and hence confounds the simplified analysis of Dupont; using age-adjusted data, we found a 36% excess risk among current estrogen users, not a 20% excess as he claims. Further, the difference in the prevalence of mammography was 15% (64% in current estrogen users and 49% in nonusers—not 31%), and the distribution of tumor size at diagnosis was similar across categories of use of estrogen therapy (an excess of small tumors would be expected among estrogen users if our findings were an artifact). Thus, as we indicated in greater detail in our discussion, surveillance

×